Citation Impact
Citing Papers
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Computational Radiomics System to Decode the Radiographic Phenotype
2017 Standout
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Microsatellite Instability in Colorectal Cancer
2010 Standout
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Chemotherapy for malignant gliomas
1988
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Suicide associated with alfa-interferon therapy for chronic viral hepatitis
1994
Delirium in elderly people
2013 Standout
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
1990 Standout
Microenvironmental regulation of therapeutic response in cancer
2014
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
1997 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin
2000
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Lung cancer: New biological insights and recent therapeutic advances
2011
Cancer stem cells revisited
2017 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Antibody therapy of cancer
2012 Standout
Diagnostic and therapeutic management of cancer of an unknown primary
2003
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
2014
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Mesenchymal Cells in Colon Cancer
2017
Monoclonal antibodies as therapeutic agents for cancer
2004
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
2017
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
2017
Parenteral Followed by Oral Ofloxacin for Nosocomial Pneumonia and Community-acquired Pneumonia Requiring Hospitalization
1992
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
2014
Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide
1996 StandoutNobel
Delirium in Older Patients
1992
MicroRNA expression profiles classify human cancers
2005 StandoutNatureNobel
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
FcRn: the neonatal Fc receptor comes of age
2007 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Artificial intelligence in radiology
2018 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
Delirium in Older Persons
2006 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Delirium in Mechanically Ventilated Patients
2001 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
2010
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Molecular Testing in Colorectal Cancer
2012
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Magnesium in Man: Implications for Health and Disease
2014 Standout
Chemotherapy of brain metastases: Current status
1984
The Tumor Lysis Syndrome
2011 Standout
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2016
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
2005
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
The Potential of Radiomic-Based Phenotyping in Precision Medicine
2016
Overview of monoclonal antibodies in cancer therapy: present and promise
2005
Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
2011
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
2008
Psychiatric Complications of Long-term Interferon Alfa Therapy
1987
The Chemistry of Neutron Capture Therapy
1998 Standout
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
2015
Delirium in Elderly Patients
2004
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
A filter incubation method for the determination of potentially crosslinkable sites in DNA in mammalian cells
1985 StandoutNobel
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
DNA strand scission and cross-linking by diaziridinylbenzoquinone (diaziquone) in human cells and relation to cell killing.
1984 StandoutNobel
Works of Robert C. Hermann being referenced
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2012
Severe neuropathy associated with low-dose recombinant interferon-alpha
1989
Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin
2000
Electroencephalographic Abnormalities in Interferon Encephalopathy: A Preliminary Report
1984
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
2003
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
2010
K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial
2009
Preliminary communication — Treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ; NSC-182986)
1983
Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).
2013
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
2013
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
2011
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
2010
Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).
2010